Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Gain Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GANX
Nasdaq
8731
https://www.gaintherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Gain Therapeutics Inc
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
- Apr 17th, 2024 1:55 pm
Insiders are Piling into These 10 Healthcare Stocks in 2024
- Apr 10th, 2024 7:30 pm
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
- Apr 10th, 2024 1:35 pm
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
- Apr 9th, 2024 1:23 pm
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
- Apr 8th, 2024 1:25 pm
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
- Apr 1st, 2024 11:01 pm
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
- Apr 1st, 2024 1:25 pm
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
- Mar 26th, 2024 12:00 pm
Gain Therapeutics to Present at Public Ventures Discovery Day
- Mar 15th, 2024 6:30 pm
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
- Mar 5th, 2024 2:45 pm
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
- Mar 5th, 2024 1:00 pm
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Feb 27th, 2024 7:00 pm
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
- Feb 14th, 2024 5:29 pm
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
- Feb 6th, 2024 2:56 pm
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
- Feb 6th, 2024 1:00 pm
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
- Jan 31st, 2024 1:00 pm
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
- Jan 24th, 2024 5:00 pm
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
- Jan 2nd, 2024 1:00 pm
Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
- Dec 14th, 2023 2:55 pm
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
- Dec 4th, 2023 1:00 pm
Scroll